Program

73
49
7
3
2
1

Journal Year Published

4
11
13
18
11
8
8
7
14
3
13
5

Author

115
183
175
135
134
127
119
118
108
90
87
81
74
57
52
50
44
43
42
34

Category

53
52
31
25
8
6
6
5
1

Keyword

55
32
23
20
18
17
14
12
11
11
10
9
8
8
8
7
7
7
7
6

Journal

9
8
7
6
4
4
4
3
3
3
3
2
2
2
2
2
2
2
1
1

NCATS Publications

Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease.


Li Z, Sakamuru S, Huang R, Brecher M, Koetzner CA, Zhang J, Chen H, Qin CF, Zhang QY, Zhou J, Kramer LD, Xia M, Li H


Antiviral Res. , 2017.

Article Pubmed

Sample image from publication page

Omics-Based Platform for Studying Chemical Toxicity Using Stem Cells.


Han Y, Zhao J, Huang R, Xia M, Wang D


J. Proteome Res. , (17), 579-589, 2018.

Article Pubmed

Sample image from publication page

Identification of Estrogen-Related Receptor α Agonists in the Tox21 Compound Library.


Lynch C, Zhao J, Huang R, Kanaya N, Bernal L, Hsieh JH, Auerbach SS, Witt KL, Merrick BA, Chen S, Teng CT, Xia M


Endocrinology , (159), 744-753, 2018.

Article Pubmed

Computational drug repositioning for rare diseases in the era of precision medicine.


Delavan B, Roberts R, Huang R, Bao W, Tong W, Liu Z


Drug Discov. Today , (23), 382-394, 2018.

Article Pubmed

Sample image from publication page

Assessment of the DNA damaging potential of environmental chemicals using a quantitative high-throughput screening approach to measure p53 activation.


Witt KL, Hsieh JH, Smith-Roe SL, Xia M, Huang R, Zhao J, Auerbach SS, Hur J, Tice RR


Environ. Mol. Mutagen. , (58), 494-507, 2017.

Article Pubmed

Sample image from publication page

Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction.


Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, Huang R, Koetzner CA, Allen CA, Jones SA, Chen H, Zhang NN, Tian M, Gao F, Lin Q, Banavali N, Zhou J, Boles N, Xia M, Kramer LD, Qin CF, Li H


Cell Res. , (27), 1046-1064, 2017.

Article Pubmed

Sample image from publication page

Why are most phospholipidosis inducers also hERG blockers?


Slavov S, Stoyanova-Slavova I, Li S, Zhao J, Huang R, Xia M, Beger R


Arch. Toxicol. , 2017.

Article Pubmed

Sample image from publication page